Impact of Helicobacter pylori immunoglobulin G levels and atrophic gastritis status on risk of metabolic syndrome

Atsushi Takeoka, Jun Tayama, Hironori Yamasaki, Masakazu Kobayashi, Sayaka Ogawa, Tatsuo Saigo, Masaki Hayashida, Susumu Shirabe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Helicobacter pylori (HP) infection is implicated in gastric and extra-gastric diseases. While gastritis-related chronic inflammation represents a known trigger of metabolic disturbances, whether metabolic syndrome (MetS) is affected by gastritis status remains unclear. We aimed to clarify the effect of HP-related gastritis on the risk of MetS. Materials and Methods: We retrospectively enrolled patients undergoing screening for MetS between 2014 and 2015. Investigations included HP-specific immunoglobulin G (IgG) antibody assays to detect HP infection, and serum pepsinogen assays to evaluate atrophic gastritis status. The risk of MetS was evaluated via multiple logistic regression analyses with two covariates: serum HP infection status (IgG levels) and atrophic gastritis status (two criteria were applied; pepsinogen I/II ratio < 3 or both pepsinogen I levels ≤ 70 μg/L and pepsinogen I/II ratio < 3). Results: Of 1,044 participants, 247 (23.7%) were HP seropositive, and 62 (6.0%) had MetS. HP seronegative and seropositive patients had similar risks of MetS. On the other hand, AG (defined in terms of serum PG I/II <3) was significant risk of MetS (OR of 2.52 [95% CI 1.05-7.52]). After stratification according to HP IgG concentration, patients with low HP infection status had the lowest MetS risk (defined as an odds ratio [OR] adjusted for age, sex, smoking, drinking and physical activity status). Taking this result as a reference, patients with negative, moderate, and high HP infection status had ORs (with 95% confidence intervals [CI]) of 2.15 (1.06-4.16), 3.69 (1.12-16.7), and 4.05 (1.05-26.8). Conclusions: HP-associated gastritis represents a risk factor for MetS. Research should determine why low and not negative HP infection status is associated with the lowest MetS risk.

Original languageEnglish
Article numbere0166588
JournalPloS one
Volume11
Issue number11
DOIs
Publication statusPublished - 2016 Nov 1
Externally publishedYes

Fingerprint

Atrophic Gastritis
gastritis
Helicobacter pylori
immunoglobulin G
metabolic syndrome
Immunoglobulin G
Pepsinogen A
Helicobacter Infections
pepsinogen
Gastritis
Pepsinogen C
Assays
infection
odds ratio
confidence interval
Serum
Logistics
Odds Ratio
Screening
Confidence Intervals

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Impact of Helicobacter pylori immunoglobulin G levels and atrophic gastritis status on risk of metabolic syndrome. / Takeoka, Atsushi; Tayama, Jun; Yamasaki, Hironori; Kobayashi, Masakazu; Ogawa, Sayaka; Saigo, Tatsuo; Hayashida, Masaki; Shirabe, Susumu.

In: PloS one, Vol. 11, No. 11, e0166588, 01.11.2016.

Research output: Contribution to journalArticle

Takeoka, A, Tayama, J, Yamasaki, H, Kobayashi, M, Ogawa, S, Saigo, T, Hayashida, M & Shirabe, S 2016, 'Impact of Helicobacter pylori immunoglobulin G levels and atrophic gastritis status on risk of metabolic syndrome', PloS one, vol. 11, no. 11, e0166588. https://doi.org/10.1371/journal.pone.0166588
Takeoka, Atsushi ; Tayama, Jun ; Yamasaki, Hironori ; Kobayashi, Masakazu ; Ogawa, Sayaka ; Saigo, Tatsuo ; Hayashida, Masaki ; Shirabe, Susumu. / Impact of Helicobacter pylori immunoglobulin G levels and atrophic gastritis status on risk of metabolic syndrome. In: PloS one. 2016 ; Vol. 11, No. 11.
@article{7cc5b5dac8694160a3fe3470b18dc2d8,
title = "Impact of Helicobacter pylori immunoglobulin G levels and atrophic gastritis status on risk of metabolic syndrome",
abstract = "Background: Helicobacter pylori (HP) infection is implicated in gastric and extra-gastric diseases. While gastritis-related chronic inflammation represents a known trigger of metabolic disturbances, whether metabolic syndrome (MetS) is affected by gastritis status remains unclear. We aimed to clarify the effect of HP-related gastritis on the risk of MetS. Materials and Methods: We retrospectively enrolled patients undergoing screening for MetS between 2014 and 2015. Investigations included HP-specific immunoglobulin G (IgG) antibody assays to detect HP infection, and serum pepsinogen assays to evaluate atrophic gastritis status. The risk of MetS was evaluated via multiple logistic regression analyses with two covariates: serum HP infection status (IgG levels) and atrophic gastritis status (two criteria were applied; pepsinogen I/II ratio < 3 or both pepsinogen I levels ≤ 70 μg/L and pepsinogen I/II ratio < 3). Results: Of 1,044 participants, 247 (23.7{\%}) were HP seropositive, and 62 (6.0{\%}) had MetS. HP seronegative and seropositive patients had similar risks of MetS. On the other hand, AG (defined in terms of serum PG I/II <3) was significant risk of MetS (OR of 2.52 [95{\%} CI 1.05-7.52]). After stratification according to HP IgG concentration, patients with low HP infection status had the lowest MetS risk (defined as an odds ratio [OR] adjusted for age, sex, smoking, drinking and physical activity status). Taking this result as a reference, patients with negative, moderate, and high HP infection status had ORs (with 95{\%} confidence intervals [CI]) of 2.15 (1.06-4.16), 3.69 (1.12-16.7), and 4.05 (1.05-26.8). Conclusions: HP-associated gastritis represents a risk factor for MetS. Research should determine why low and not negative HP infection status is associated with the lowest MetS risk.",
author = "Atsushi Takeoka and Jun Tayama and Hironori Yamasaki and Masakazu Kobayashi and Sayaka Ogawa and Tatsuo Saigo and Masaki Hayashida and Susumu Shirabe",
year = "2016",
month = "11",
day = "1",
doi = "10.1371/journal.pone.0166588",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Impact of Helicobacter pylori immunoglobulin G levels and atrophic gastritis status on risk of metabolic syndrome

AU - Takeoka, Atsushi

AU - Tayama, Jun

AU - Yamasaki, Hironori

AU - Kobayashi, Masakazu

AU - Ogawa, Sayaka

AU - Saigo, Tatsuo

AU - Hayashida, Masaki

AU - Shirabe, Susumu

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Helicobacter pylori (HP) infection is implicated in gastric and extra-gastric diseases. While gastritis-related chronic inflammation represents a known trigger of metabolic disturbances, whether metabolic syndrome (MetS) is affected by gastritis status remains unclear. We aimed to clarify the effect of HP-related gastritis on the risk of MetS. Materials and Methods: We retrospectively enrolled patients undergoing screening for MetS between 2014 and 2015. Investigations included HP-specific immunoglobulin G (IgG) antibody assays to detect HP infection, and serum pepsinogen assays to evaluate atrophic gastritis status. The risk of MetS was evaluated via multiple logistic regression analyses with two covariates: serum HP infection status (IgG levels) and atrophic gastritis status (two criteria were applied; pepsinogen I/II ratio < 3 or both pepsinogen I levels ≤ 70 μg/L and pepsinogen I/II ratio < 3). Results: Of 1,044 participants, 247 (23.7%) were HP seropositive, and 62 (6.0%) had MetS. HP seronegative and seropositive patients had similar risks of MetS. On the other hand, AG (defined in terms of serum PG I/II <3) was significant risk of MetS (OR of 2.52 [95% CI 1.05-7.52]). After stratification according to HP IgG concentration, patients with low HP infection status had the lowest MetS risk (defined as an odds ratio [OR] adjusted for age, sex, smoking, drinking and physical activity status). Taking this result as a reference, patients with negative, moderate, and high HP infection status had ORs (with 95% confidence intervals [CI]) of 2.15 (1.06-4.16), 3.69 (1.12-16.7), and 4.05 (1.05-26.8). Conclusions: HP-associated gastritis represents a risk factor for MetS. Research should determine why low and not negative HP infection status is associated with the lowest MetS risk.

AB - Background: Helicobacter pylori (HP) infection is implicated in gastric and extra-gastric diseases. While gastritis-related chronic inflammation represents a known trigger of metabolic disturbances, whether metabolic syndrome (MetS) is affected by gastritis status remains unclear. We aimed to clarify the effect of HP-related gastritis on the risk of MetS. Materials and Methods: We retrospectively enrolled patients undergoing screening for MetS between 2014 and 2015. Investigations included HP-specific immunoglobulin G (IgG) antibody assays to detect HP infection, and serum pepsinogen assays to evaluate atrophic gastritis status. The risk of MetS was evaluated via multiple logistic regression analyses with two covariates: serum HP infection status (IgG levels) and atrophic gastritis status (two criteria were applied; pepsinogen I/II ratio < 3 or both pepsinogen I levels ≤ 70 μg/L and pepsinogen I/II ratio < 3). Results: Of 1,044 participants, 247 (23.7%) were HP seropositive, and 62 (6.0%) had MetS. HP seronegative and seropositive patients had similar risks of MetS. On the other hand, AG (defined in terms of serum PG I/II <3) was significant risk of MetS (OR of 2.52 [95% CI 1.05-7.52]). After stratification according to HP IgG concentration, patients with low HP infection status had the lowest MetS risk (defined as an odds ratio [OR] adjusted for age, sex, smoking, drinking and physical activity status). Taking this result as a reference, patients with negative, moderate, and high HP infection status had ORs (with 95% confidence intervals [CI]) of 2.15 (1.06-4.16), 3.69 (1.12-16.7), and 4.05 (1.05-26.8). Conclusions: HP-associated gastritis represents a risk factor for MetS. Research should determine why low and not negative HP infection status is associated with the lowest MetS risk.

UR - http://www.scopus.com/inward/record.url?scp=84995580449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995580449&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0166588

DO - 10.1371/journal.pone.0166588

M3 - Article

C2 - 27851820

AN - SCOPUS:84995580449

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0166588

ER -